PL3082858T3 - Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu - Google Patents

Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu

Info

Publication number: PL3082858T3
Authority: PL; Poland
Prior art keywords: adrenomedullin; cancer; therapy; binder; adrenomedullin binder
Prior art date: 2013-12-20

Application number

PL14830958T

Other languages

English (en)

Inventor

Andreas Bergmann

Original Assignee

Angiobiomed Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-20

Filing date

2014-12-19

Publication date

2021-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3082858(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-19 Application filed by Angiobiomed Gmbh filed Critical Angiobiomed Gmbh

2021-09-27 Publication of PL3082858T3 publication Critical patent/PL3082858T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL14830958T 2013-12-20 2014-12-19 Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu PL3082858T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP13199000		2013-12-20
EP14830958.6A EP3082858B1 (en)	2013-12-20	2014-12-19	Adrenomedullin binder for use in therapy of cancer
PCT/EP2014/078870 WO2015092021A1 (en)	2013-12-20	2014-12-19	Adrenomedullin binder for use in therapy of cancer

Publications (1)

Publication Number	Publication Date
PL3082858T3 true PL3082858T3 (pl)	2021-09-27

Family

ID=49876456

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14830958T PL3082858T3 (pl)	2013-12-20	2014-12-19	Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu

Country Status (6)

Country	Link
US (1)	US10793626B2 (pl)
EP (1)	EP3082858B1 (pl)
JP (1)	JP6673847B2 (pl)
ES (1)	ES2865303T3 (pl)
PL (1)	PL3082858T3 (pl)
WO (1)	WO2015092021A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021099600A1 (en) *	2019-11-22	2021-05-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
AU2021238591A1 (en) *	2020-03-16	2022-11-17	Adrenomed Ag	Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69602756T2 (de)	1995-08-18	2000-02-10	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville	Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
US20050175619A1 (en) *	2004-02-05	2005-08-11	Robert Duffy	Methods of producing antibody conjugates
ES2582652T3 (es) *	2006-02-10	2016-09-14	Genentech, Inc.	Anticuerpos anti-FGF19 y métodos de uso de los mismos
LT3553084T (lt) *	2011-11-16	2023-03-10	Adrenomed Ag	Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne-ig karkasas, skirtas organų funkcijos sutrikimo arba organų nepakankamumo profilaktikai arba sumažinimui paciento, sergančio lėtine arba ūmine liga arba esančio ūminės būklės, organizme
EP2780370B1 (en) *	2011-11-16	2019-09-25	AdrenoMed AG	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation

2014
- 2014-12-19 PL PL14830958T patent/PL3082858T3/pl unknown
- 2014-12-19 EP EP14830958.6A patent/EP3082858B1/en not_active Revoked
- 2014-12-19 WO PCT/EP2014/078870 patent/WO2015092021A1/en not_active Ceased
- 2014-12-19 US US15/105,712 patent/US10793626B2/en active Active
- 2014-12-19 JP JP2016560037A patent/JP6673847B2/ja active Active
- 2014-12-19 ES ES14830958T patent/ES2865303T3/es active Active

Also Published As

Publication number	Publication date
ES2865303T3 (es)	2021-10-15
US20160319007A1 (en)	2016-11-03
EP3082858A1 (en)	2016-10-26
JP6673847B2 (ja)	2020-03-25
JP2017508781A (ja)	2017-03-30
EP3082858B1 (en)	2021-01-27
WO2015092021A1 (en)	2015-06-25
US10793626B2 (en)	2020-10-06

Publication	Publication Date	Title
IL274318A (en)	2020-06-30	Cancer treatment with rapamycin target site kinase inhibitors
IL245731A0 (en)	2016-07-31	Combined treatment for cancer
GB2516814B (en)	2016-08-31	Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB201322725D0 (en)	2014-02-05	Cancer therapy
SG11201510751YA (en)	2016-03-30	Composition and vaccine for treating prostate cancer
DK3010519T3 (en)	2021-05-17	Oncolytic adenovirus for use in a treatment of brain cancer
IL245281A0 (en)	2016-06-30	Methods and preparations for the treatment of cancer
ZA201406706B (en)	2016-05-25	Treatment of cancer with tor kinase inhibitors
ZA201406708B (en)	2016-05-25	Treatment of cancer with tor kinase inhibitors
IL234641B (en)	2020-04-30	Cancer treatment with rapamycin target site kinase inhibitors
SG11201509707QA (en)	2015-12-30	Cancer therapy
IL244353A0 (en)	2016-04-21	Compounds and use for cancer treatment
SG11201507847UA (en)	2015-11-27	Cancer therapy
SG11201508878WA (en)	2015-11-27	Methods of treating cancer
ZA201507755B (en)	2019-11-27	Tumor-selective combination therapy
IL238453A0 (en)	2015-06-30	Trans-clomiphene for use in cancer treatment
EP2961412A4 (en)	2016-11-09	CANCER THERAPY
SG11201509596YA (en)	2015-12-30	Methods of treating cancer
SI2872176T1 (sl)	2017-08-31	Karboranilporfirin za uporabo pri zdravljenju raka
PL3082858T3 (pl)	2021-09-27	Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu
GB201518731D0 (en)	2015-12-09	Tumour Therapy
GB201317213D0 (en)	2013-11-13	Cancer Therapy
GB201322958D0 (en)	2014-02-12	Uses of oligouronates in cancer treatment
PL3010513T3 (pl)	2019-11-29	Skojarzenie RO5503781 i kapecytabiny do leczenia raka
GB201308365D0 (en)	2013-06-19	Tumour therapy